The global biotechnology market was valued at $1.55 trillion in 2023 and is projected to grow at a rate of 13.96% annually until 2030. We regularly look at the headlines of start-ups in the space securing funding and what that will enable them to pursue as a company, but we don’t often get a chance ...

Next-generation sequencing (NGS) is an emerging technology to determine DNA/RNA sequences for whole genome or specific regions of interest at a lower cost than traditional sequencing and a major disruptor in the biotech space. With NGS data having a major impact in the field of genomics research, ...

We were delighted to be joined on the Data in Biotech podcast by Wolfgang Halter from Merck Life Science for a deep dive into Bayesian Optimization for design of experiments (DOE). This approach to setting up experimental campaigns to leverage the information gained from previous experiments to ...

The potential impact of AI on the diagnosis and development of treatment for neurological diseases is significant. In August last year, a study demonstrated how AI could detect markers of Parkinson’s disease up to seven years before any symptoms appeared. This is the tip of the iceberg, and in our ...

Real-world data (RWD) is having a significant impact on biotech, pharma, and healthcare. Along with giving additional insight into clinical trials that will help to improve patient outcomes, McKinsey estimates that, over the next three to five years, an average top-20 pharmaceutical company could ...

One of the great things about the Data in Biotech podcast is that we get to look in depth at so many aspects of data science impacting the biotech and pharma space. This episode looked at the topic of knowledge graphs, what they are, why they are useful, and how LLMs, AI, and Machine learning are ...

With MarketsandMarkets forecasting that the health data market will reach $900 million by 2028, it was fantastic to sit down with Vera Mucaj, CSO at Datavant, to discuss how data is changing the healthcare landscape. Her background gives her real insight into both the scientific and technological ...

As we have often seen with guests who are founders, the inspiration for their business proposition is rooted in frustrations they have encountered in previous roles. Harry Rickerby, Co-Founder and CEO at Briefly Bio, is no exception. He talks about his new venture and the challenges that led him to ...

One of the goals of Data in Biotech is to build a community of professionals interested in how data can impact biotech organizations and create a space for discussion. Only one month in, we are starting to see that community grow as one of our previous guests, Markus Gershater from Synthace, put us ...